Literature DB >> 22027329

Clinical hurdles and possible solutions in the implementation of closed-loop control in type 1 diabetes mellitus.

Howard Zisser1.   

Abstract

From an engineering perspective, controlling blood glucose appears to be a fairly straightforward single input (glucose), single output (insulin) control problem. Unfortunately, mimicking Mother Nature turns out to be a complex endeavor. The primary hurdle in developing a useful, safe closed-loop control algorithm for an artificial pancreas is the time delays associated with current continuous glucose monitors and subcutaneously delivered insulins. This article will provide a brief history of the artificial pancreas, outline the main clinical hurdles restricting its current implementation, and list possible solutions for success.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027329      PMCID: PMC3208892          DOI: 10.1177/193229681100500537

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  18 in total

Review 1.  Continuous glucose monitoring and closed-loop systems.

Authors:  R Hovorka
Journal:  Diabet Med       Date:  2006-01       Impact factor: 4.359

2.  Pancreatic Extracts in the Treatment of Diabetes Mellitus.

Authors:  F G Banting; C H Best; J B Collip; W R Campbell; A A Fletcher
Journal:  Can Med Assoc J       Date:  1922-03       Impact factor: 8.262

3.  Use of a novel fluorescent glucose sensor in volunteer subjects with type 1 diabetes mellitus.

Authors:  Thomas Peyser; Howard Zisser; Uzma Khan; Lois Jovanovič; Wendy Bevier; Matt Romey; Jeff Suri; Paul Strasma; Stephanie Tiaden; Soya Gamsey
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia--monitor, alert, and locate.

Authors:  Eyal Dassau; Lois Jovanovic; Francis J Doyle; Howard C Zisser
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

5.  Current status of portable insulin infusion devices. Satellite workshop on portable insulin infusion devices. (Preceding the XVth annual meeting of the European Society for Clinical Investigation) 18-19 March 1981, Basel, Switzerland.

Authors:  U Keller; D S Schade
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

Review 6.  Variability of insulin absorption and insulin action.

Authors:  Lutz Heinemann
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

7.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes.

Authors:  Aaron J Kowalski
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

8.  Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.

Authors:  K Rave; E Potocka; L Heinemann; T Heise; A H Boss; M Marino; D Costello; R Chen
Journal:  Diabetes Obes Metab       Date:  2009-05-19       Impact factor: 6.577

9.  Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects.

Authors:  A Giacca; A Caumo; G Galimberti; G Petrella; M C Librenti; M Scavini; G Pozza; P Micossi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.

Authors:  Stuart A Weinzimer; Garry M Steil; Karena L Swan; Jim Dziura; Natalie Kurtz; William V Tamborlane
Journal:  Diabetes Care       Date:  2008-02-05       Impact factor: 19.112

View more
  10 in total

1.  Artificial pancreas goes outpatient: a new diabetes ecosystem.

Authors:  Eric Renard; Claudio Cobelli; Howard C Zisser; Boris P Kovatchev
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

2.  Periodic-zone model predictive control for diurnal closed-loop operation of an artificial pancreas.

Authors:  Ravi Gondhalekar; Eyal Dassau; Howard C Zisser; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

3.  Velocity-weighting to prevent controller-induced hypoglycemia in MPC of an artificial pancreas to treat T1DM.

Authors:  Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  Proc Am Control Conf       Date:  2015-07-30

4.  MPC Design for Rapid Pump-Attenuation and Expedited Hyperglycemia Response to Treat T1DM with an Artificial Pancreas.

Authors:  Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  Proc Am Control Conf       Date:  2014-07-21

5.  State Estimation with Sensor Recalibrations and Asynchronous Measurements for MPC of an Artificial Pancreas to Treat T1DM.

Authors:  Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  Proc IFAC World Congress       Date:  2014-08

6.  Periodic zone-MPC with asymmetric costs for outpatient-ready safety of an artificial pancreas to treat type 1 diabetes.

Authors:  Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  Automatica (Oxf)       Date:  2016-06-01       Impact factor: 5.944

7.  Reducing Glucose Variability Due to Meals and Postprandial Exercise in T1DM Using Switched LPV Control: In Silico Studies.

Authors:  Patricio H Colmegna; Ricardo S Sánchez-Peña; Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

8.  Switched LPV Glucose Control in Type 1 Diabetes.

Authors:  Patricio H Colmegna; Ricardo S Sanchez-Pena; Ravi Gondhalekar; Eyal Dassau; Frank J Doyle
Journal:  IEEE Trans Biomed Eng       Date:  2015-10-05       Impact factor: 4.538

9.  Patient perspectives on personalized glucose advisory systems for type 1 diabetes management.

Authors:  Jaclyn A Shepard; Linda Gonder-Frederick; Karen Vajda; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2012-08-02       Impact factor: 6.118

Review 10.  A Review of Safety and Design Requirements of the Artificial Pancreas.

Authors:  Helga Blauw; Patrick Keith-Hynes; Robin Koops; J Hans DeVries
Journal:  Ann Biomed Eng       Date:  2016-06-28       Impact factor: 3.934

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.